Taro Announces Results of Its Extraordinary General Meeting of Shareholders

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced that the Company held an extraordinary general meeting of shareholders today, March 27, 2014, at 14 Hakitor Street, Haifa Bay 26110, Israel (the “Extraordinary General Meeting”). IVS Associates, Inc., a leading provider of independent election services, independently tabulated and certified the voting results of the Extraordinary General Meeting.

As Taro previously announced, the purpose of the Extraordinary General Meeting was the ratification of certain resolutions adopted by the Company’s shareholders at its 2013 annual general meeting. These resolutions were approved and ratified and include the following: (i) approval of the Company’s compensation policy, (ii) approval of compensation to three of its directors (Dilip Shanghvi, Sudhir Valia and Kal Sundaram), and (iii) re-election of its external directors (Ilana Avidov Mor and Dan Biran).

The proposals offered by a shareholder of the Company to elect Mr. Ben-Ami Rosenfeld and Ms. Adi Bershadsky as External Directors to the Board of Directors were again not approved.

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.